Hillhouse Capital and Chinese healthcare-focused investment firm Decheng Capital have led a US$60 million series B found in San Diego-based DNA sequencing platform developer Omniome, Inc. New investors including Lam Research Capital, Nan Fung Life Sciences, and existing investors including ARCH Venture Partners, Domain Associates, Biomatics Capital Partners and Altitude Life Science Ventures, also participated in the round, according to Omniome’s announcement. Founded in 2013, Omniome develops a DNA sequencing platform with its Sequencing By Binding™ (SBB™) technology.